ZEISS to expand myopia solutions in China with NMPA’s approval of ZEISS PT LUNANA phakic intraocular lens

ZEISS is introducing its PT LUNANA phakic intraocular lens (pIOL) to the Chinese market. A pIOL is an artificial lens surgically implanted into the eye without removing the natural lens. This device is designed to correct refractive errors like myopia (nearsightedness) by complementing the eye's existing lens, offering an alternative to glasses, contact lenses, or some forms of laser surgery.

The description of PT LUNANA as a "next-generation aspheric" pIOL indicates a focus on advanced lens design. While specific details are not provided, the term suggests enhancements aimed at improving optical quality or performance compared to previous models.

The NMPA approval and product showcase at CIIE position ZEISS to address a significant need, as myopia is identified as a "growing major public health challenge" in China. This move aims to provide a surgical option for vision correction within a market facing increasing demand for such solutions.